



# Next biomanufacturing hub

**BIOMANUFACTURING** Supported by long-term state funding, Poland is poised to become a technology transfer and product development hub for globally active biotechs. Gdansk-based Polpharma Biologics provides all biomanufacturing skills and capabilities needed to take foot in the highly interesting Central and Eastern Europe market.

Beyond 2020, the Polish government plans to invest heavily into building scientific partnerships, expanding technology transfer and boosting advanced manufacturing capacities. The city of Gdansk is determined to become Poland's precision medicine hub by robust investments being made in the country's leading biobank and the rapid construction of an ultra-modern university hospital.

## **Polpharma Group – a regional powerhouse and partner of choice**

Polpharma Biologics, an emerging leader in biopharmaceutical outsourcing, is a name to remember for your business development agenda. Today, the Polpharma Group, with its 80-year heritage in developing and manufacturing fine medicines, is a pharmaceu-



tical powerhouse. Commercial operations stretch across the region and the company's development and manufacturing network is designed as a hub and spoke product supply framework poised for rapid growth. Tomorrow the company will be a principal partner in Central and Eastern Europe for the development and manufacture of biopharmaceuticals.

## **Want to outsource with confidence?**

Polpharma Biologics offers early mover advantage in a way which has the ability to offset risk and make budgets go further. Contract Research,

Development & Manufacturing supports rapid market access, drives efficiencies in development programmes and moreover tech transfer may qualify for external development financing. Flexibility is a valuable ingredient and there is a thirst for new technologies, which you can turn into opportunity.

## **Looking for a principal partner in Europe?**

Polpharma Biologics is an ideal partner for international biotech companies looking for flexible, small-scale cell culture development (up to 1,000 litres) and commercial scale manufacture. Regulatory, development and manufacturing processes are fully compliant to EMA and FDA approval. Global players have already placed their trust in the company and are jointly develop-

ing products with Polpharma for global markets. And so can you.

### Outsource with upside – make your budgets go further

Polpharma Biologics offers outsourced development and manufacturing with a plus, particularly:

- Flexible outsourcing of global R,D & M programmes to drive efficiency – time and cost advantage
- Using local D & M as a route to market in Europe, CIS & MENA – accelerate growth
- Transferring technology to benefit from financial incentives.

For companies looking to enter this region with their brands, the company's footprint confers real advantage in terms of market access where local manufacturing is an important key to market access and success. In the future, the company will be offering large scale volume manufacture and is also evaluating bacterial production.

It is worth remembering that partnerships are at the core of the company's success. The company has an

important role to play in global development programmes where flexibility and efficiency play a vital role – beyond established markets. Polpharma Biologics is a preferential licensing partner in the new emerging markets of continental Europe, CIS & MENA where biotech is poised to take off and near-shoring is a nascent, yet rapidly growing trend.

### Why Polpharma Biologics?

- Flexible, biopharmaceutical outsourcing for EU, CIS & MENA – regulatory, development and manufacturing – an approach driven by quality, efficiency and cost advantage
- A focused and dynamic team of international professionals with significant experience in the regulation, development and manufacture of biopharmaceuticals gained in leading global companies
- A powerful licensing partner for global biotech companies looking for serious growth in new export markets.

### Contact

[office.biologics@polpharma.com](mailto:office.biologics@polpharma.com)  
[www.polpharmabiologics.com](http://www.polpharmabiologics.com)



Pictures: xxx



## Communication and dissemination services for EU-funded consortia

Are you looking for a communications partner in Horizon 2020 and other R&D programmes? As an SME with more than 25 years of experience in biotechnology/life sciences, **BIOCOM** is the perfect partner for your communication and dissemination needs.



- Project branding and preparation of communications materials
- Creation, maintenance and updating of the project website
- Press and media work, incl. videos
- Organisation of conferences and workshops

### Interested?

For more information, just head to [www.biocom.de/consortia](http://www.biocom.de/consortia) or contact Dr. Boris Mannhardt at [b.mannhardt@biocom.de](mailto:b.mannhardt@biocom.de)